| Literature DB >> 26356319 |
C Mauz-Körholz1, T Lange1, D Hasenclever2, B Burkhardt3, A C Feller4, W Dörffel5, R Kluge6, D Vordermark7, D Körholz1.
Abstract
Nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL) is a very rare disease in childhood and adolescence. In Germany, about 15 newly diagnosed patients present with this disease annually; this number comprises less than 10% of all pediatric Hodgkin lymphoma cases. Since the EuroNet-PHL-LP1 trial for early stage nLPHL patients stopped recruiting in Germany in October 2014, the GPOH-HD writing committee reviewed the literature and decided to deliver treatment recommendations for childhood and adolescent nLPHL patients. These guidelines shall be applicable to young nLPHL patients in European countries that will no longer be able to participate in nLPHL trials for young patients. Therefore, the EuroNet-PHL-nLPHL-registry will be installed to provide quality assured central review of staging and response assessment for registered patients by the Central Review Board of EuroNet-PHL in Halle/Leipzig, Germany. © Georg Thieme Verlag KG Stuttgart · New York.Entities:
Mesh：
Year: 2015 PMID： 26356319 DOI： 10.1055/s-0035-1559664
Source DB: PubMed Journal: Klin Padiatr ISSN： 0300-8630 Impact factor: 1.349